Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vor Biopharma Inc.

0.7020
+0.01562.27%
Post-market: 0.70200.00000.00%16:00 EDT
Volume:526.40K
Turnover:355.95K
Market Cap:87.65M
PE:-0.41
High:0.7400
Open:0.7077
Low:0.6371
Close:0.6864
Loading ...

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to Its Board of Directors

THOMSON REUTERS
·
08 Jan

Press Release: Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Dow Jones
·
08 Jan

JMP Securities Adjusts Price Target on Vor Biopharma to $6 From $12, Keeps Market Outperform Rating

MT Newswires Live
·
31 Dec 2024

Analysts Are Bullish on Top Healthcare Stocks: Precigen (PGEN), Vor Biopharma (VOR)

TIPRANKS
·
28 Dec 2024

U.S. RESEARCH ROUNDUP-Kratos Defense and Security Solutions, Masimo and Servicetitan

Reuters
·
28 Dec 2024

Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

GuruFocus.com
·
28 Dec 2024

Wedbush Cuts Price Target on Vor Biopharma to $7 From $11, Maintains Outperform Rating

MT Newswires Live
·
28 Dec 2024

Vor Biopharma Inc : Wedbush Cuts Target Price to $7 From $11

THOMSON REUTERS
·
28 Dec 2024

Vor Biopharma Expects to Raise $55.6 Million From Private Placement; Shares Up

MT Newswires Live
·
27 Dec 2024

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

TIPRANKS
·
27 Dec 2024

Vor Bio prices 55.87M shares at 99.425c in private placement

TIPRANKS
·
27 Dec 2024

Press Release: Vor Bio Announces $55.6 Million Private Placement

Dow Jones
·
27 Dec 2024

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Simply Wall St.
·
24 Dec 2024

Vor Biopharma Price Target Maintained With a $17.50/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Vor Bio trem-cel relapse-rate remains low, says Oppenheimer

TIPRANKS
·
10 Dec 2024

Vor Biopharma’s Strategic Advances and Promising Clinical Trial Results Justify Buy Rating

TIPRANKS
·
10 Dec 2024

Vor Bio announces updated data from Phase 1/2 VBP1-1 study

TIPRANKS
·
09 Dec 2024

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design

THOMSON REUTERS
·
09 Dec 2024

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

GlobeNewswire
·
09 Dec 2024

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)

TIPRANKS
·
25 Nov 2024